Loading...
Market
Most cited benefit of WATCHMAN FLX™ over anticoagulants by end of 2025?
2
Resolution / Starting Odds
Reduced bleeding risk • 25%
Improved patient compliance • 25%
Lower long-term costs • 25%
Other benefits • 25%
Surveys and studies published in medical journals
Story
OPTION Trial: WATCHMAN FLX™ Device Reduces Bleeding Risk Over 36 Months in Atrial Fibrillation Patients, AHA 2024 Reports
Nov 16, 2024, 07:58 PM
Recent findings presented at the American Heart Association's 2024 conference indicate that left atrial appendage closure, specifically using the Boston Scientific WATCHMAN FLX™ device, may offer significant advantages over traditional oral anticoagulation therapy for patients with atrial fibrillation. The OPTION trial results reveal that following atrial fibrillation ablation, patients who underwent left atrial appendage closure experienced a lower risk of major bleeding events compared to those on blood thinners. Additionally, the outcomes regarding stroke, embolism, and mortality were found to be noninferior to those receiving oral anticoagulation at the 36-month mark. These findings are supported by other studies, including a randomized trial comparing the WATCHMAN device to anticoagulants, which also showed a reduction in major bleeding without an increase in adverse events. The implications of these results could influence treatment strategies for managing atrial fibrillation, particularly in patients at risk for stroke and bleeding complications.
View original story
Similar markets
Dietary changes • 25%
Increased physical activity • 25%
Smoking reduction • 25%
Improved medical treatments • 25%
Increased patient survival rate • 25%
Improved quality of life • 25%
Reduced need for medication • 25%
Other • 25%
Reduced surgery count • 25%
Faster recovery times • 25%
Lower complication rates • 25%
Cost savings • 25%
Faster recovery time • 25%
Reduced pain • 25%
Shorter hospital stay • 25%
Improved surgical precision • 25%
Increased surgical precision • 25%
Reduced surgery time • 25%
Improved patient outcomes • 25%
Enhanced training for surgeons • 25%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Ease of Administration • 25%
Cost Effectiveness • 25%
Patient Preference • 25%
Clinical Effectiveness • 25%
Weight Reduction • 25%
Cardiovascular Risk Reduction • 25%
Improved Heart Failure Symptoms • 25%
Other • 25%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Improved physical health • 25%
Improved mental health • 25%
Improved social life • 25%
Other • 25%
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%